Skip to main content

Advertisement

ADVERTISEMENT

Poster CS-065

Pure Hypochlorous Acid Preserved Wound Cleanser (HAPWOC*) in the Management of Acute or Chronic Complex Wounds When Using Standard Negative Pressure Wound

Michael D Kalos, DNP, RN, CWOCN

Antonietta Galati, D.Pod.M. – Clinical Coordinator, Chiropody Clinic, The Michener Institute of Education at UHN; Nancy McNaughton, PhD, – Education Scholar, The Michener Institute of Education at UHN; Sahar Hussain, B.A – Coordinator, Learning, Innovation, and Research, The Michener Institute of Education at UHN

Symposium on Advanced Wound Care Spring Spring 2022

Introduction: Hypochlorous Acid Preserved Wound Cleanser(HAPWOC)* has improved wound outcomes as described in evidenced-based practice. The product formulation allows efficient removal of wound debris/microbes. We standardized for the management of acute or chronic complex wounds as an irrigation medium when using Standard Negative Pressure Wound Therapy(NPWT).

Subjects and Settings: 454-bed metropolitan Level I Trauma Center in the Midwestern United States. HAPWOC was adopted by the Certified Wound Ostomy & Continence Nurse(CWOCN) services for all wounds. Patients, 18 years or older with pressure injuries, trauma/lacerations/surgical standard conditions indicative for NPWT were treated with HAPWOC. Observations of the patients were conducted May and June 2021. NPWT application, and during dressing changes, HAPWOC irrigation used 50-60ml in a 10ml syringe. HAPWOC was provided to the bedside RN via hospital material supply. We present three cases to illustrate use in conjunction with standard NPWT.

Results: 50 patients had HAPWOC pre-application/during changes of NPWT. Use demonstrated a return to a healthy-stable tissue base. Wounds remained moist and non-malodorous when cleansed with HAPWOC. Use was suggested as the irrigation for home or outpatient until wound resolution.

Conclusion: Healing is a complex process. for the human body. Requiring hydration, nutrition, microclimate, protection, and pH balance. HAPWOC with known efficacy against biofilms is ideally formulated for use in conjunction with NPWT via effective debris/microbe removal. HAPWOC standardized use demonstrated no complications as evidenced by the high number of patients managed (50 patients) in a short period. Increased access to RNs as opposed to CWOCN “only” accounts for proper use and standardization. Due to short stay many patients are discharged without full wound closure. This typical short length limits the long term assessment and gauging of wound resolution. Further, limits acute care/inpatient hospital based wound care studies. We suggest continued use of HAPWOC post-inpatient discharge be done by Long Term Care Hospitals, Home Care Agencies and Rehabilitative Centers to maintain wounds on the same healthy trajectory that we see during HAPWOC use during hospitalization.

References

1. Davis AH. The seriousness of chronic venous disease: a review of real-world evidence. Adv Ther. 2019;36(suppl 1):5–12. doi:10.1007/s12325-019-0881-7

2. Day A, Alkhalil A, Carney BC, Hoffman HN, Moffatt LT, Shupp JW. Disruption of biofilms and neutralization of bacteria using hypochlorous acid solution: an in vivo and in vitroevaluation. Adv Skin Wound Care. 2017;30(12):543–551. doi:10.1097/01.ASW.0000526607.80113.66

3. Harriott MM, Bhindi N, Kassis S, Summitt B, Perdikis G, Wormer BA, Rankin TM, Kaoutzanis C, Samaha M, Stratton C, Schmitz JE. Comparative Antimicrobial Activity of CommercialWound Care Solutions on Bacterial and Fungal Biofilms. Ann Plast Surg. 2019 Oct;83(4):404-410. https://pubmed.ncbi.nlm.nih.gov/31524733/

4. Robson MC. Treating chronic wounds with hypochlorous acid disrupts biofilm. Wound Prevention and Management 2020;66 (5):9-10.https://www.todayswoundclinic.com/articles/treating-chronic-wounds-hypochlorous-acid-disrupts-biofilm

5. Harriott MM, Bhindi N, Kassis S, Summitt B, Perdikis G, Wormer BA, Rankin TM, Kaoutzanis C, Samaha M, Stratton C, Schmitz JE. Comparative Antimicrobial Activity of CommercialWound Care Solutions on Bacterial and Fungal Biofilms. Ann Plast Surg. 2019 Oct;83(4):404-410. doi: 10.1097/SAP.0000000000001996. PMID: 31524733; PMCID: PMC6750017. https://pubmed.ncbi.nlm.nih.gov/31524733/

Advertisement

Advertisement

Advertisement